Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents

Li, Zejun; Chu, Taiwei

doi:10.2174/138161212799315849

Cited by 21 publications

(11 citation statements)

References 98 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2][3][4] Among all the imidazole compounds, 2-nitroimidazoles have higher electron affinities and are the most commonly used hypoxia markers when labeled with positron emission tomography (PET) radionuclides. 5,6 Problems associated with PET radionuclides include low resolution, high background counts, and the use of radioactive tracers. In addition, PET systems are expensive for routine clinical use in longitudinal imaging assessments over the course of chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates

Xu¹,

Zanganeh²,

Mohammad³

et al. 2013

J. Biomed. Opt

View full text Add to dashboard Cite

Abstract. Tumor hypoxia is a major indicator of treatment resistance to chemotherapeutic drugs, and fluorescence optical tomography has tremendous potential to provide clinically useful, functional information by identifying tumor hypoxia. The synthesis of a 2-nitroimidazole-indocyanine green conjugate using a piperazine linker (piperazine-2-nitroimidazole-ICG) capable of robust fluorescent imaging of tumor hypoxia is described. In vivo mouse tumor imaging studies were completed and demonstrate an improved imaging capability of the new dye relative to an earlier version of the dye that was synthesized with an ethanolamine linker (ethanolamine-2-nitroimidazole-ICG). Mouse tumors located at imaging depths of 1.5 and 2.0 cm in a turbid medium were imaged at various time points after intravenous injection of the dyes. On average, the reconstructed maximum fluorescence concentration of the tumors injected with piperazine-2-nitroimidazole-ICG was twofold higher than that injected with ethanolamine-2-nitroimidazole-ICG within 3 h postinjection period and 1.6 to 1.7 times higher beyond 3 h postinjection. The untargeted bis-carboxylic acid ICG completely washed out after 3 h postinjection. Thus, the optimal window to assess tumor hypoxia is beyond 3 h postinjection. These findings were supported with fluorescence images of histological sections of tumor samples and an immunohistochemistry technique for identifying tumor hypoxia.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates

Xu¹,

Zanganeh²,

Mohammad³

et al. 2013

J. Biomed. Opt

View full text Add to dashboard Cite

show abstract

“…[ 18 F]FMISO is considered to be the gold standard for tracing hypoxia with PET. Recently, Li and Chu [54] have provided an overview of the radionuclide labeled hypoxia-imaging agents developed in the past decade. In that review, the radionuclide labeled bioreducible compounds including nitroimidazoles and other redox-sensitive compounds such as Tc-BnAO and Cu-ATSM are summarized.…”

Section: Potential Hypoxia Imaging Agentsmentioning

confidence: 99%

Radiopharmaceuticals in China: current status and prospects

Jia¹,

Liu

2014

Radiochimica Acta

View full text Add to dashboard Cite

The review provides an overview of the current status of radiopharmaceuticals in China for in vivo clinical use and also describes some important advances in the past three decades. Development of the diagnostic and therapeutic radiopharmaceuticals as well as basic research on radiopharmaceutical chemistry are being introduced. The radiotracers developed in China include: (1) Brain perfusion imaging agents and CNS radiotracers for -amyloid plaques, 1 receptors, and dopamine D 2 or D 4 receptors;(2) 99m Tc-and 18 F-labeled myocardial perfusion imaging agents; (3) tumor imaging agents including integrin-targeting radiotracer, novel sentinel lymph node imaging agents, hypoxia imaging agents, 99m Tc-labeled glucose derivatives, 2 receptor imaging agents, folate receptor imaging agents, and potential radiotracers for imaging of human telomerase reverse transcriptase expression; (4) Potential infection imaging agents; (5) Potential asialoglycoprotein receptor imaging agents; (6) Other imaging agents. Moreover, some prospects of research and development of radiopharmaceuticals in the near future are discussed.

show abstract

“…There has been a growing interest in hypoxic selectivity based on ligand receptor interaction, and dual-or multi-modality molecular imaging has also attracted increasing attention. 34 However, applications for imaging hypoxia on targeted therapy are still in very early stages, which may be promising in monitoring the efficacy of antiangiogenesis-targeted therapies.…”

Section: Surrogate Molecular Imagingmentioning

confidence: 99%

New strategy for monitoring targeted therapy: molecular imaging

Teng¹,

Meng²,

Sun³

et al. 2013

IJN

View full text Add to dashboard Cite

Targeted therapy is becoming an increasingly important component in the treatment of cancer. How to accurately monitor targeted therapy has been crucial in clinical practice. The traditional approach to monitor treatment through imaging has relied on assessing the change of tumor size by refined World Health Organization criteria, or more recently, by the Response Evaluation Criteria in Solid Tumors. However, these criteria, which are based on the change of tumor size, show some limitations for evaluating targeted therapy. Currently, genetic alterations are identified with prognostic as well as predictive potential concerning the use of molecularly targeted drugs. Conversely, considering the limitations of invasiveness and the issue of expression heterogeneity, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively, and has been a particularly attractive tool for monitoring treatment in clinical cancer practice. This review focuses on the applications of different kinds of molecular imaging including positron emission tomography-, magnetic resonance imaging-, ultrasonography-, and computed tomography-based imaging strategies on monitoring targeted therapy. In addition, the key challenges of molecular imaging are addressed to successfully translate these promising techniques in the future.

show abstract

Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents

Cited by 21 publications

References 98 publications

Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates

Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates

Radiopharmaceuticals in China: current status and prospects

New strategy for monitoring targeted therapy: molecular imaging

Contact Info

Product

Resources

About